Search research articles

ACERCA DE JoVE

Visión General Liderazgo Blog Centro de Ayuda JoVE

AUTORES

Proceso de Publicación Consejo Editorial Alcance y Políticas Revisión por Pares Preguntas Frecuentes Enviar

BIBLIOTECARIOS

Testimonios Suscripciones Acceso Recursos Consejo Asesor de Bibliotecas Preguntas Frecuentes

INVESTIGACIÓN

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archivo

EDUCACIÓN

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Centro de Recursos para Profesores Sitio de Profesores

Términos y Condiciones de Uso

Política de Privacidad

Videos de Conceptos Relacionados

Tissue Renewal without Stem Cells

Tissue Renewal without Stem Cells

After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...

Liver Regeneration

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...

Liver Histology

Liver Histology

The microscopic anatomy of the liver is a complex and intricate system that comprises numerous structural units known as liver lobules, each of which is comparable in size to a sesame seed. These hexagonal structures consist of plates of liver cells or hepatocytes, which are characterized by their versatility and abundance of cellular apparatus like rough and smooth ER, Golgi apparatus, peroxisomes, and mitochondria.
Hepatocytes perform a variety of essential functions. They secrete...

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por

Same author

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].

Journal of hepatology·2026

Same author

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Alimentary pharmacology & therapeutics·2026

Same author

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.

Journal of hepatology·2025

Same author

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.

Journal of hepatology·2025

Same author

Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.

The Lancet regional health. Europe·2025

Same author

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.

Lancet (London, England)·2025

Search research articles

Video Experimental Relacionado

Updated: Jul 6, 2026

Isolation of CD133+ Liver Stem Cells for Clonal Expansion

Isolation of CD133+ Liver Stem Cells for Clonal Expansion

Published on: October 10, 2011

El carcinoma hepatocelular es un carcinoma hepatocelular.

Josep M Llovet¹, Andrew Burroughs, Jordi Bruix

¹Barcelona-Clínic Liver Cancer Group, Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Cli;nic i Provincial, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.

Lancet (London, England)

|December 12, 2003

Resumen

Este resumen es generado por máquina.

La vigilancia del carcinoma hepatocelular (CCH) cada 6 meses ayuda al diagnóstico temprano en pacientes con cirrosis de alto riesgo. La detección temprana permite tratamientos curativos, mejorando las tasas de supervivencia para el cáncer de hígado.

Más Videos Relacionados

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

Videos de Experimentos Relacionados

Last Updated: Jul 6, 2026

Isolation of CD133+ Liver Stem Cells for Clonal Expansion

Isolation of CD133+ Liver Stem Cells for Clonal Expansion

Published on: October 10, 2011

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

Área de la Ciencia:

Hepatología Hepatología.
Oncología Oncología.
Gastroenterología y Gastroenterología.

Sus antecedentes:

El carcinoma hepatocelular (HCC) es un importante cáncer mundial con una incidencia creciente.
Las infecciones por el virus de la hepatitis B y C son factores clave del HCC.
Los pacientes con cirrosis enfrentan el mayor riesgo y requieren un monitoreo regular.

Objetivo del estudio:

Revisar las estrategias actuales de manejo para el carcinoma hepatocelular (CCH).
Para resaltar la importancia del diagnóstico temprano y las opciones de tratamiento para HCC.
Evaluar la eficacia de los tratamientos paliativos para el CCH avanzado.

Principales métodos:

Revisión de los resultados del tratamiento para HCC.
Análisis de 63 ensayos controlados aleatorios sobre tratamientos paliativos para el CCH.
Metaanálisis de la eficacia de la quimioembolisización en el CCH no resecable.

Principales resultados:

La vigilancia cada 6 meses puede conducir a un diagnóstico temprano de HCC.
Los tratamientos curativos (resección, trasplante) son aplicables al 30% de los pacientes en los países occidentales y Japón, lo que da >50% de supervivencia a 5 años.
La quimioembolisización es el único tratamiento paliativo que se ha demostrado que mejora la supervivencia en pacientes seleccionados con CHC no resecable.

Conclusiones:

La detección temprana a través de la vigilancia es crucial para mejorar los resultados de HCC.
El trasplante de hígado, aunque es efectivo, está limitado por la disponibilidad de donantes.
La quimioembolización ofrece un beneficio de supervivencia para casos específicos de HCC no resecable.